The role of cannabinoids in neuroanatomic alterations in cannabis users

Biological Psychiatry

Volumn 79, Issue 7, 2016, Pages e17-e31

  Lorenzetti, Valentina ^a,b   Solowij, Nadia ^c   Yücel, Murat ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Cannabidiol; Cannabinoids; Cannabis; CBD; Hippocampus; Prefrontal; THC

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; DRONABINOL; CANNABIDIOL; CANNABINOID RECEPTOR AGONIST;

AMYGDALOID NUCLEUS; ASSOCIATION; BRAIN REGION; BRAIN SIZE; CANNABIS USE; CEREBELLUM; HIPPOCAMPUS; HUMAN; NEUROANATOMY; NEUROBIOLOGY; NEUROIMAGING; ONSET AGE; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; BRAIN MAPPING; CANNABIS SMOKING; DRUG EFFECTS; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR;

BRAIN MAPPING; CANNABIDIOL; CANNABINOID RECEPTOR AGONISTS; DRONABINOL; HIPPOCAMPUS; HUMANS; MARIJUANA SMOKING; PREFRONTAL CORTEX; TIME FACTORS;

EID: 84962531536     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2015.11.013     Document Type: Review

References (141)

1. Swift W, Wong A, Li KM, Arnold JC, McGregor IS (2013): Analysis of cannabis seizures in NSW, Australia: Cannabis potency and cannabinoid profile. PloS One 8:e70052.
2. Gaoni Y, Mechoulam R (1971): The isolation and structure of delta-1- tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 93:217-224.
3. Volkow ND, Baler RD, Compton WM, Weiss SRB (2014): Adverse health effects of marijuana use. N Engl J Med 370: 2219-2227.
4. Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. (2015): Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a casecontrol study. Lancet Psychiatry 2:233-238.
5. Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, McGuire PK (2012): Neural mechanisms for the cannabinoid modulation of cognition and affect in man: A critical review of neuroimaging studies. Curr Pharm Des 18:5045-5054.
6. Zuardi AW, Crippa JAS, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, et al. (2012): A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 18:5131-5140.
7. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009): Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515-527.
8. Lupica CR, Riegel AC, Hoffman AF (2004): Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol 143: 227-234.
9. United Nations Office on Drugs and Crime (2009): Why does cannabis potency matter? In: World Drug Report 2009. New York: United Nations.
10. Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. (2014): Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 40:1509-1517.
11. Substance Abuse and Mental Health Services Administration (2013): Drug Abuse Warning Network, 2011: National Estimates of Drug- Related Emergency Department Visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration.
12. Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, et al. (2012): Acute effects of a single, oral dose of Δ9- tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 18:4966-4979.
13. Fusar-Poli P, Allen P, Bhattacharyya S, Crippa JA, Mechelli A, Borgwardt S, et al. (2010): Modulation of effective connectivity during emotional processing by delta-9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 13:421-432.
14. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. (2010): Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764-774.
15. Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, et al. (2009): Cannabis and anxiety: A critical review of the evidence. Hum Psychopharmacol 24:515-523.
16. Lawstone J, Borella A, Robinson JK, Whitaker-Azmitia PM (2000): Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55, 212-2. Brain Res 877:407-410.
17. Chan GCK, Hinds TR, Impey S, Storm DR (1998): Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol. J Neurosci 18:5322-5332.
18. Landfield PW, Caldwallader LB, Vinsant S (1988): Quantitative changes in hippocampal structure following long-term exposure to Δ9-tetrahydrocannabinol: Possible mediation by glucocorticoid systems. Brain Res 443:47-62.
19. Scallet AC, Uemura E, Andrews A, Ali SF, McMillan DE, Paule MG, et al. (1987): Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res 436:193-198.
20. Heath RG, Fitzjarrell AT, Fontana CJ, Garey RE (1980): Cannabis sativa: Effects on brain function and ultrastructure in rhesus monkeys. Biol Psychiatry 15:657-690.
21. Kolb B, Gorny G, Limebeer CL, Parker LA (2006): Chronic treatment with delta-9-tetrahydrocannabinol alters the structure of neurons in the nucleus accumbens shell and medial prefrontal cortex of rats. Synapse 60:429-436.
22. Downer E, Boland B, Fogarty M, Campbell VCA (2001): Delta-9- tetrahydrocannabinol induces the apoptotic pathway in cultured cortical neurons via activation of the CB1 receptor. Neuroreport, 12, 3973-3978.
23. Harper JW, Heath RG, Myers WA (1977): Effects of Cannabis sativa on ultrastructure of the synapse in monkey brain. J Neurosci Res 3:87-93.
24. Schiavon A, Soares L, Bonato J, Milani H, Guimarães F, Weffort de Oliveira R (2014): Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotox Res 26:307-316.
25. Hermann D, Schneider M (2012): Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: A critical review. Curr Pharm Des 18:4897-4905.
26. Schubart CD, Sommer IEC, Fusar-Poli P, de Witte L, Kahn RS, Boks MPM (2014): Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol 24:51-64.
27. Bhattacharyya S (2014): Neurobiological and neurocognitive basis of the effects of cannabinoids in animals and man: Therapeutic potential of cannabinoids in psychiatry. Curr Pharm Des 20:2069-2071.
28. Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, et al. (2012): Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 42:391-400.
29. Morgan CJ, Curran HV (2008): Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192:306-307.
30. Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G, et al. (2011): Diminished gray matter in the hippocampus of cannabis users: Possible protective effects of cannabidiol. Drug Alcohol Depend 114:242-245.
31. Glass M, Faull RLM, Dragunow M (1997): Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299.
32. Bhattacharyya S (2009): Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764.
33. Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Prata D, et al. (2012): Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 17:1152-1155.
34. Bhattacharyya S, Falkenberg I, Martin-Santos R, Atakan Z, Crippa JA, Giampietro V, et al. (2015): Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacology 40:1343-1352.
35. Morrison PD, Nottage J, Stone JM, Bhattacharyya S, Tunstall N, Brenneisen R, et al. (2011): Disruption of frontal theta coherence by delta9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology 36:827-836.
36. Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O'Carroll C, et al. (2009): Modulation of mediotemporal and ventrostriatal function in humans by Δ9-tetrahydrocannabinol: A neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 66:442-451.
37. Bhattacharyya S, Crippa J, Martin-Santos R, Winton-Brown T, Fusar-Poli P (2009): Imaging the neural effects of cannabinoids: Current status and future opportunities for psychopharmacology. Curr Pharm Des 15:2603-2614.
38. Lorenzetti V, Solowij N, Whittle S, Fornito A, Lubman DI, Pantelis C, et al. (2015): Gross morphological brain changes with chronic, heavy cannabis use. Br J Psychiatry 206:77-78.
39. Weiland BJ, Thayer RE, Depue BE, Sabbineni A, Bryan AD, Hutchison KE (2015): Daily marijuana use is not associated with brain morphometric measures in adolescents or adults. J Neurosci 35:1505-1512.
40. Battistella G, Fornari E, Annoni J-M, Chtioui H, Dao K, Fabritius M, et al. (2014): Long-term effects of cannabis on brain structure. Neuropsychopharmacology 39:2041-2048.
41. Gilman JM, Kuster JK, Lee S, Lee MJ, Kim BW, Makris N, et al. (2014): Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. J Neurosci 34:5529-5538.
42. Filbey FM, Aslan S, Calhoun VD, Spence JS, Damaraju E, Caprihan A, et al. (2014): Long-term effects of marijuana use on the brain. Proc Natl Acad Sci 111:16913-16918.
43. Yip SW, DeVito EE, Kober H, Worhunsky PD, Carroll KM, Potenza MN (2014): Pretreatment measures of brain structure and rewardprocessing brain function in cannabis dependence: An exploratory study of relationships with abstinence during behavioral treatment. Drug Alcohol Depend 140:33-41.
44. Batalla A, Soriano-Mas C, Lopez-Sola M, Torrens M, Crippa JA, Bhattacharyya S, et al. (2014): Modulation of brain structure by catechol-O-methyltransferase Val(158) Met polymorphism in chronic cannabis users. Addict Biol 19:722-732.
45. Solowij N, Walterfang M, Lubman DI, Whittle S, Lorenzetti V, Styner M, et al. (2013): Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophr Res 143: 179-184.
46. Schacht JP, Hutchison KE, Filbey FM (2012): Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology 37:2368-2376.
47. Lorenzetti V, Solowij N, Fornito A, Lubman DI, Yucel M (2014): The association between regular cannabis exposure and alterations of human brain morphology: An updated review of the literature. Curr Pharm Des 20:2138-2167.
48. Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yücel M (2010): Structural MRI findings in long-term cannabis users: What do we know? Subst Use Misuse 45:1787-1808.
49. Lopez-Larson MP, Bogorodzki P, Rogowska J, McGlade E, King JB, Terry J, et al. (2011): Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behav Brain Res 220:164-172.
50. Solowij N, Yücel M, Respondek C, Whittle S, Lindsay E, Pantelis C, et al. (2011): Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychol Med 41:2349-2359.
51. Ashtari M, Avants B, Cyckowski L, Cervellione KL, Roofeh D, Cook P, et al. (2011): Medial temporal structures and memory functions in adolescents with heavy cannabis use. J Psychiatr Res 45:1055-1066.
52. McQueeny T, Padula CB, Price J, Medina KL, Logan P, Tapert SF (2011): Gender effects on amygdala morphometry in adolescent marijuana users. Behav Brain Res 224:128-134.
53. Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE (2012): Grey matter alterations associated with cannabis use: Results of a VBM study in heavy cannabis users and healthy controls. Neuroimage 59:3845-3851.
54. Churchwell JC, Lopez-Larson M, Yurgelun-Todd DA (2010): Altered frontal cortical volume and decision making in adolescent cannabis users. Front Psychol 1:225.
55. Mata I, Perez-Iglesias R, Roiz-Santianez R, Tordesillas-Gutierrez D, Pazos A, Gutierrez A, et al. (2010): Gyrification brain abnormalities associated with adolescence and early-adulthood cannabis use. Brain Res. 1317:297-304.
56. Medina KL, Nagel BJ, Tapert SF (2010): Abnormal cerebellar morphometry in abstinent adolescent marijuana users. Psychiatry Res 182:152-159.
57. Medina KL, McQueeny T, Nagel BJ, Hanson KL, Yang TT, Tapert SF (2009): Prefrontal cortex morphometry in abstinent adolescent marijuana users: Subtle gender effects. Addict Biol 14:457-468.
58. Yücel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, et al. (2008): Regional brain abnormalities associated with heavy long-term cannabis use. Arch Gen Psychiatry 65:1-8.
59. Medina KL, Nagel BJ, Park A, McQueeny T, Tapert SF (2007): Depressive symptoms in adolescents: Associations with white matter volume and marijuana use. J Child Psychol Psychiatry 48:592-600.
60. Medina KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF (2007): Effects of alcohol and combined marijuana and alcohol use hippocampal volume and asymmetry. Neurotoxicol Teratol 29:141-152.
61. Jager G, Van Hell HH, De Win MML, Kahn RS, Van Den Brink W, Van Ree JM, et al. (2007): Effects of frequent cannabis use on hippocampal activity during an associative learning memory task. Eur Psychopharmacol 17:289-297.
62. Tzilos GK, Cintron CB, Wood JB, Simpson NS, Young AD, Pope HG Jr, et al. (2005): Lack of hippocampal volume change in long-term heavy cannabis users. Am J Addict 14:64-72.
63. Matochik JA, Eldeth DA, Cadet DA, Bolla KI (2005): Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend 77:23-30.
64. Block RI, O'Leary DS, Ehrhardt JC, Augustinack JC, Ghoneim MM, Arndt S, et al. (2000): Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport 11:491-496.
65. Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE, Provenzale J (2000): Brain morphological changes and early marijuana use. A MRI and PET study. J Addict Dis 19:1-22.
66. Hannerz J, Hindmarsh T (1983): Neurological and neuroradiological examination of chronic cannabis smokers. Ann Neurol 13:207-210.
67. Kuehnle J, Mendelson JH, Davis KR, New PF (1977): Computed tomographic examination of heavy marijuana smokers. JAMA 237:1231-1232.
68. Co BT, Goodwin DW, Gado M, Mickhael M, Hill SY (1977): Absence of cerebral atrophy in chronic cannabis users. Evaluation by computerized transaxial tomography. JAMA 237:1229-1230.
69. Stefanis C (1976): Biological aspects of cannabis use. In: Petersen R, editor. The International Challenge of Drug Abuse. Rockville, MD: National Institute on Drug Abuse, 149-178.
70. Campbell AMG, Evans M, Thomson JLG, Williams MJ (1971): Cerebral atrophy in young cannabis smokers. Lancet 2:1219-1224.
71. Cousijn J, Goudriaan AE, Ridderinkhof KR, van den Brink W, Veltman DJ, Wiers RW (2013): Neural responses associated with cue-reactivity in frequent cannabis users. Addict Biol 18:570-580.
72. Yücel M, Lorenzetti V, Suo V, Zalesky A, Fornito A, Fernandez F, et al. (2015): Marijuana and brain health: Hippocampal injury, protection and recovery. Presented at Organization of the Human Brain Mapping, June 14-18, 2015, Honolulu, Hawaii.
73. Adams IB, Martin BR (1996): Cannabis: Pharmacology and toxicology in animals and humans. Addiction 91:1585-1614.
74. Monnet-Tschudi F, Hazekamp A, Perret N, Zurich M-G, Mangin P, Giroud C, et al. (2008): Delta-9-tetrahydrocannabinol accumulation, metabolism and cell-type-specific adverse effects in aggregating brain cell cultures. Toxicol Appl Pharmacol 228:8-16.
75. Rocchetti M, Crescini A, Borgwardt S, Caverzasi E, Politi P, Atakan Z, et al. (2013): Is cannabis neurotoxic for the healthy brain? A metaanalytical review of structural brain alterations in non-psychotic users. Psychiatry Clin Neurosci 67:483-492.
76. Scallet AC (1991): Neurotoxicology of cannabis and THC: A review of chronic exposure studies in animals. Pharmacol Biochem Behav 40:671-676.
77. Tonini R, Ciardo S, Cerovic M, Rubino T, Parolaro D, Mazzanti M, et al. (2006): ERK-dependent modulation of cerebellar synaptic plasticity after chronic Δ9-tetrahydrocannabinol exposure. J Neurosci 26:5810-5818.
78. Martin BR, Sim-Selley LJ, Selley DE (2004): Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci 25:325-330.
79. Rubino T, Vigano D, Realini N, Guidali C, Braida D, Capurro V, et al. (2008): Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: Behavioral and biochemical correlates. Neuropsychopharmacology 33:2760-2771.
80. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim- Selley LJ (1999): Chronic Δ9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73:2447-2459.
81. Burston JJ, Wiley JL, Craig AA, Selley DE, Sim-Selley LJ (2010): Regional enhancement of cannabinoid CB1 receptor desensitization in female adolescent rats following repeated delta-tetrahydrocannabinol exposure. Br J Pharmacol 161:103-112.
82. Sim-Selley LJ (2003): Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15:91-119.
83. Hill SY, Muddasani S, Prasad K, Nutche J, Steinhauer SR, Scanlon J, et al. (2007): Cerebellar volume in offspring from multiplex alcohol dependence families. Biol Psychiatry 61:41-47.
84. Paus T (2005): Mapping brain maturation and cognitive development during adolescence. Trends Cogn Sci 9:60-68.
85. Herning RI, Better WE, Tate K, Cadet JL (2005): Cerebrovascular perfusion in marijuana users during a month of monitored abstinence. Neurology 64:488-493.
86. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki G (2006): Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nat Neurosci 9:1526-1533.
87. Skosnik PD, D'Souza DC, Steinmetz AB, Edwards CR, Vollmer JM, Hetrick WP, et al. (2012): The effect of chronic cannabinoids on broadband EEG neural oscillations in humans. Neuropsychopharmacology 37:2184-2193.
88. Heath RG (1976): Marihuana and Δ9-THC: Acute and chronic effects on brain function of monkeys. In: Brande MC, Szara S, editors. Pharmacology of Marihuana. New York: Raven Press, 345-356.
89. Heath RG (1976): Cannabis sativa derivates: Effects on brain function of monkeys. In: Nahas GG, editor. Marihuana: Chemistry, Biochemistry and Cellular Effects. New York: Springer-Verlag, 507-519.
90. Rogers BP, Morgan VL, Newton AT, Gore JC (2007): Assessing functional connectivity in the human brain by fMRI. Magn Reson Imaging 25:1347-1357.
91. Rockland KS, Van Hoesen GW (1999): Some temporal and parietal cortical connections converge in CA1 of the primate hippocampus. Cerebral Cortex 9:232-237.
92. Whitlock JR, Sutherland RJ, Witter MP, Moser M-B, Moser EI (2008): Navigating from hippocampus to parietal cortex. Proc Natl Acad Sci U S A 105:14755-14762.
93. Vincent JL, Kahn I, Snyder AZ, Raichle ME, Buckner RL (2008): Evidence for a frontoparietal control system revealed by intrinsic functional connectivity. J Neurophysiol 100:3328-3342.
94. Catenoix H, Magnin M, Guenot M, Isnard J, Mauguiere F, Ryvlin P (2005): Hippocampal-orbitofrontal connectivity in human: An electrical stimulation study. Clin Neurophysiol 116:1779-1784.
95. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD (2009): Neurodegenerative diseases target large-scale human brain networks. Neuron 62:42-52.
96. Harding IH, Solowij N, Harrison BJ, Takagi M, Lorenzetti V, Lubman DI, et al. (2012): Functional connectivity in brain networks underlying cognitive control in chronic cannabis users. Neuropsychopharmacology 37:1923-1933.
97. Zalesky A, Solowij N, Yucel M, Lubman DI, Takagi M, Harding IH, et al. (2012): Effect of long-term cannabis use on axonal fibre connectivity. Brain 135:2245-2255.
98. Hyman SE, Malenka RC, Nestler EJ (2006): Neural mechanisms of addiction: The role of reward-related learning and memory. Annu Rev Neurosci 29:565-598.
99. Ramus SJ, Davis JB, Donahue RJ, Discenza CB, Waite AA (2007): Interactions between the orbitofrontal cortex and the hippocampal memory system during the storage of long-term memory. Ann N Y Acad Sci 1121:216-231.
100. Rueda MR, Posner MI, Rothbart MK (2005): The development of executive attention: Contributions to the emergence of selfregulation. Dev Neuropsychol 28:573-594.
101. Mesulam MM (1990): Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Ann Neurol 28:597-613.
102. Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PC, et al. (2011): Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology 216:131-144.
103. Takagi M, Yücel M, Cotton SM, Baliz Y, Tucker A, Elkins K, et al. (2011): Verbal memory, learning, and executive functioning among adolescent inhalant and cannabis users. J Stud Alcohol Drugs 72:96-105.
104. Takagi M, Lubman DI, Cotton S, Fornito A, Baliz Y, Tucker A, et al. (2011): Executive control among adolescent inhalant and cannabis users. Drug Alcohol Rev 30:629-637.
105. McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015): Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol, 172, 737-753.
106. Thomas A, Baillie G, Phillips A, Razdan R, Ross R, Pertwee R (2007): Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150: 613-623.
107. Pertwee RG, Ross RA (2002): Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66:101-121.
108. Batalla A, Bhattacharyya S, Yucel M, Fusar-Poli P, Crippa JA, Nogue S, et al. (2013): Structural and functional imaging studies in chronic cannabis users: A systematic review of adolescent and adult findings. PloS One 8:e55821.
109. Skopp G, Strohbeck-Kuehner P, Mann K, Hermann D (2007): Deposition of cannabinoids in hair after long-term use of cannabis. Forensic Sci Int 170:46-50.
110. Khajuria H, Nayak BP (2014): Detection of Δ9-tetrahydrocannabinol (THC) in hair using GC-MS. Egypt J Forensic Sci 4:17-20.
111. Buchan BJ, Dennis ML, Tims FM, Diamond GS (2002): Cannabis use: Consistency and validity of self-report, on-site urine testing and laboratory testing. Addiction 97:98-108.
112. Clarke RC, Watson DP (2007): Cannabis and the natural cannabis medicine. In: ElSohly MA, editor. Marijuana and the Cannabinoids. New York: Humana Press, 1-15.
113. Van der Kooy F, Pomahacova B, Verpoorte R (2009): Cannabis smoke condensate II: Influence of tobacco on tetrahydrocannabinol levels. Inhal Toxicol 21:87-90.
114. Lorenzetti V, Cousijn J (2015): Cannabis use disorders and brain morphology. In: Preedy VR, editor. Neuropathology of Drug Addictions and Substance Misuse: Common Substances of Abuse- Tobacco, Alcohol, Cannabinoids and Opioids. London: Elsevier.
115. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. (2002): Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287:1123-1131.
116. Yücel M, Lubman DI, Solowij N, Brewer WJ (2007): Understanding drug addiction: A neuropsychological perspective. Aust N Z J Psychiatry 41:957-968.
117. Solowij N, Battisti R (2008): The chronic effects of cannabis on memory in humans: A review. Curr Drug Abuse Rev 1:81-98.
118. Verstraete AG (2004): Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit 26:200-205.
119. Goodwin RS, Darwin WD, Chiang CN, Shih M, Li S-H, Huestis MA (2008): Urinary elimination of 11-nor-9-carboxy-Δ9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol 32:562-569.
120. Drummer OH (2005): Review: Pharmacokinetics of illicit drugs in oral fluid. Forensic Sci Int 150:133-142.
121. Beck O, Stephanson N, Sandqvist S, Franck J (2013): Detection of drugs of abuse in exhaled breath using a device for rapid collection: Comparison with plasma, urine and self-reporting in 47 drug users. J Breath Res 7:026006.
122. American Psychiatric Association (1996): Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press.
123. American Psychiatric Association (2013): Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Press.
124. Adamson SJ, Sellman JD (2003): A prototype screening instrument for cannabis use disorder: The Cannabis Use Disorders Identification Test (CUDIT) in an alcohol-dependent clinical sample. Drug Alcohol Rev 22:309-315.
125. Buchan BJ, Dennis ML, Tims FM, Diamond GS (2002): Cannabis use: Consistency and validity of self-report, on-site urine testing and laboratory testing. Addiction 97:98.
126. Brown SA, Myers MG, Lippke L, Tapert SF, Stewart DG, Vik PW (1998): Psychometric evaluation of the Customary Drinking and Drug Use Record (CDDR): A measure of adolescent alcohol and drug involvement. J Stud Alcohol Drugs 59:427.
127. Fureman B, Parikh G, Bragg A, McLellan A (1990): Addiction Severity Index. A Guide to Training and Supervising ASI Interviews. Philadelphia: University of Pennsylvania/Philadelphia VAMC, Center for Studies of Addiction.
128. Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Sheehan KH, et al. (1997): The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: Reliability and validity according to the CIDI. Eur Psychiatry 12:224-231.
129. Budney AJ, Novy PL, Hughes JR (1999): Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94:1311-1322.
130. Koob GF (2009): Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56(suppl 1):18-31.
131. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW (1999): Associative processes in addiction and reward: The role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci 877:412-438.
132. Ongur D, Price JL (2000): The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. Cereb Cortex 10:206-219.
133. Hamilton CM, Strader LC, Pratt JG, Maiese D, Hendershot T, Kwok RK, et al. (2011): The PhenX Toolkit: Get the most from your measures. Am J Epidemiol 174:253-260.
134. Sobell LC, Sobell MB (1992): Timeline Follow-Back: A Technique for Assessing Self-Reported Alcohol Consumption. Totowa, NJ: Humana Press.
135. Morgan CJ, Schafer G, Freeman TP, Curran HV (2010): Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: Naturalistic study [corrected]. Br J Psychiatry 197: 285-290.
136. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. (2009): High-potency cannabis and the risk of psychosis. Br J Psychiatry 195:488-491.
137. Bohn MJ, Babor TF, Kranzler HR (1995): The Alcohol Use Disorders Identification Test (AUDIT): Validation of a screening instrument for use in medical settings. J Stud Alcohol 56:423-432.
138. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO (1991): The Fagerström test for nicotine dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict 86:1119-1127.
139. Rosenbaum CD, Carreiro SP, Babu KM (2012): Here today, gone tomorrow ... and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 8:15-32.
140. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL (2012): "Spice" and "K2" herbal highs: A case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 21:320-326.
141. Musshoff F, Madea B, Kernbach-Wighton G, Bicker W, Kneisel S, Hutter M, et al. (2014): Driving under the influence of synthetic cannabinoids ("Spice"): A case series. Int J Legal Med 128:59-64.